Lastwika KJ, et al. Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small-cell lung cancer. Sci Transl Med. 2023 Jan 11;15(678):eadd8469.
In this new study (Lastwika KJ, et al. 2023) researchers developed a high-dimensional technique to identify specific antibodies associated with small cell lung cancer (SCLC). These antibodies target unique antigens linked to SCLC. By isolating these antibodies and their corresponding antigens, the researchers were able to accurately detect early-stage SCLC.
The study also revealed that the immune system can produce antibodies against proteins that are not typically associated with SCLC. This happens when post-translational modifications (PTMs) occur in the proteins, creating new targets for the immune system.
These findings not only enhance our understanding of SCLC development but also have broader implications for immune-related biomarkers. The research could potentially lead to the development of strategies for early cancer detection and antibody-based treatments.
The researchers used four Triple A polyclonal antibodies from Atlas Antibodies (anti-TFRC HPA028598, anti-SPINT2 HPA011101, anti-CA9 HPA055207, and anti-PLD3 HPA012800) to run immunohistochemistry (IHC) on tissue samples from 62 SCLC cases and six lung tissue controls.
Read the full article here.